3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
12
Terminated
3
Recruiting
2
Withdrawn
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
2
Lymphoid
2
Conditions
Hematologic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
beta-Thalassemia
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Graft vs Host Disease
2
Anemia, Refractory, with Excess of Blasts
2
Virus Diseases
1
Thalassemia
1
Primary Myelofibrosis
1
Non-Malignant Neoplasm
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, B-Cell
1
Influenza, Human
1
Fanconi Anemia
1
Cytopenia
1
Chromosome Aberrations
1
Chromosome 7, monosomy
1
Anemia, Sickle Cell
1
Interventions
Dexamethasone
87
daratumumab
49
Lenalidomide
49
pomalidomide
33
Bortezomib
32
Cyclophosphamide
31
carfilzomib
25
Calcium Dobesilate
21
talquetamab
19
fludarabine
18
isatuximab
16
iberdomide
16
Magnetic Resonance Spectroscopy
16
Specimen Handling
15
Biopsy
14
selinexor
12
Melphalan
11
belantamab mafodotin
10
dexamethasone acetate
9
dexamethasone 21-phosphate
8
elotuzumab
7
auricularum
7
venetoclax
6
tocilizumab
5
fludarabine phosphate
5
X-Rays
5
Blood Specimen Collection
5
ruxolitinib
4
Methylprednisolone
4
Injections
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Multiple Myeloma
×
thymoglobulin
×
Clear all
NCT04888741
2026-05-05
MoTD
University of Birmingham
Phase 2
Recruiting
400 enrolled
NCT03852407
2022-10-12
HLA
University of Liege
Phase 2
Recruiting
114 enrolled